Kirin has been granted a patent for a monoclonal antibody that binds to human CCR1, inhibiting its activation by CCL15. The antibody can be used in therapeutic and diagnostic agents for CCR1-related diseases. GlobalData’s report on Kirin gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Kirin Holdings Co Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kirin, Lactobacilli-based drug compositions was a key innovation area identified from patents. Kirin's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Monoclonal antibody inhibiting ccr1 activation by ccl15

Source: United States Patent and Trademark Office (USPTO). Credit: Kirin Holdings Co Ltd

A recently granted patent (Publication Number: US11912775B2) discloses a monoclonal antibody or antibody fragment that binds to a specific region of the human CC chemokine receptor 1 (CCR1) and inhibits its activation by a human CC chemokine ligand 15 (CCL15). The patent lists various specific antibodies with defined amino acid sequences that exhibit this inhibitory activity. Additionally, the antibody is capable of inhibiting the migration of human CCR1-expressing cells induced by CCL15, further highlighting its potential therapeutic applications in modulating immune responses.

Moreover, the patent covers genetically recombinant antibodies, antibody fragments, and derivatives of the antibody that can be conjugated with various compounds such as radioisotopes, low molecular drugs, high molecular drugs, proteins, or other antibody drugs. These derivatives aim to enhance the therapeutic efficacy of the monoclonal antibody in targeting CCR1. The patent also includes methods for producing the monoclonal antibody, hybridomas that produce the antibody, nucleic acids encoding the antibody, transformant cells containing the nucleic acid, and methods for producing the antibody from these cells. Overall, the patent provides a detailed framework for the development and application of monoclonal antibodies targeting CCR1 for potential therapeutic interventions.

To know more about GlobalData’s detailed insights on Kirin, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.